Full Press Release Details
BOULDER, Colo.,May 12, 2026/PRNewswire/ -- Edgewise Therapeutics, Inc. (Nasdaq:EWTX), a leading muscle disease biopharmaceutical company, today announced that Edgewise leadership will present at the RBC Capital Markets Global Healthcare Conference on Wednesday, May 20, 2026, at 10:00 am ET.
The presentation will be webcast live; a link for the webcast can be found on the EdgewiseEvents & Presentations pageand will be accessible for replay for a limited time following the conference. It is recommended that users connect to the live webcast several minutes prior to the start to ensure a timely connection.
About Edgewise Therapeutics
Edgewise Therapeutics is a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The Company's deep expertise in muscle physiology is driving a new generation of novel therapeutics. Sevasemten is an orally administered first-in-class fast skeletal myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies. EDG-7500 is a novel cardiac sarcomere modulator for the treatment of symptomatic hypertrophic cardiomyopathy, currently in Phase 2 clinical development. EDG-15400 is a novel cardiac sarcomere modulator for the treatment of heart failure, currently in Phase 1 clinical development. The entire team at Edgewise is dedicated to our mission: changing the lives of patients and families affected by serious muscle diseases. To learn more, go toedgewisetx.comor follow us onLinkedInandX.